Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
featured
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or

measurable disease
cancer
bendamustine
refractory follicular lymphoma
obinutuzumab
  • 560 views
  • 23 Nov, 2020
  • 12 locations
featured
A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab,or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or

lymphoma
lymphomas
b-cell lymphoma
  • 72 views
  • 14 Dec, 2020
  • 21 locations
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

The purpose of this study is to compare ofatumumab & chlorambucil (O-Chl) versus ofatumumab & bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not fit

thrombocytopenia
chronic lymphocytic leukemia
anemia
cyclophosphamide
ofatumumab
  • 436 views
  • 08 Nov, 2020
  • 1 location
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell

acalabrutinib
cyclin d1
bendamustine
rituximab
  • 1270 views
  • 20 Jun, 2021
  • 246 locations
Treatment With Lenalidomide Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Define maximum tolerable dose of the combination lenalidomide, bendamustine, prednisone.

prednisone
refractory multiple myeloma
cancer
lenalidomide
  • 64 views
  • 08 Nov, 2020
Rituximab Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Prospective, multicenter, phase II trial designed to evaluate whether the addition of Venetoclax after rituximab, bendamustine and cytarabine (R-BAC) to high risk patients with mantle cell

cyclin d1
cytarabine
hepatitis b core antibody
venetoclax
renal function tests
  • 14 views
  • 25 Mar, 2021
  • 49 locations
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

, researchers hope to determine whether the combined drugs are successful in treating HCL. Pentostatin and bendamustine are two anti-cancer drugs that have been used to treat different kinds of blood

  • 0 views
  • 22 Jun, 2021
  • 1 location
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation.

salvage therapy
bendamustine
anthracyclines
cell transplantation
rituximab
  • 16 views
  • 07 Nov, 2020
  • 1 location
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

tumor burden
platelet count
bendamustine
rituximab
neutrophil count
  • 37 views
  • 26 Mar, 2021
  • 37 locations
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival.

chemoimmunotherapy
chronic lymphocytic leukemia
cyclophosphamide
venetoclax
measurable disease
  • 1222 views
  • 08 May, 2021
  • 243 locations